Clarify the Role of Monoclonal Antibodies in Treatment of COVID-19

Casirivimab/imdevimab will be the second monoclonal antibody treatment authorized for OUTpatients with COVID-19.

This combo will be an alternative to bamlanivimab as a single-dose IV infusion. And more are in the works.

These "mabs" block SARS-CoV-2 from entering cells.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote